This website will continue to be updated as new information becomes available.
Novo Nordisk continues to see strong interest in our prescription-only medicine Wegovy® for chronic weight management. Obesity is a serious, chronic, and misunderstood disease which affects many of our friends, colleagues, families, and loved ones. We take our responsibility to meet the needs of people living with obesity and the healthcare professionals who treat them very seriously.
We understand how frustrating this situation is for the communities we serve and appreciate everyone’s patience as we continue to navigate significant demand for Wegovy®. Please know our commitment to the obesity community is a long-term one and we are investing significantly to build capacity to meet this increasing demand. A second contract manufacturing organization (CMO) initiated production in April 2023 to help increase Wegovy® supply and a third site at one of our current CMOs is expected soon. We have solid plans in place for continuously increasing Wegovy® capacity in the coming years.
Important Guidance: Filling Your Wegovy® Prescription
We remain committed to driving meaningful change for people living with obesity and supporting healthcare providers partnering on their care. As part of this commitment, we want to ensure that Wegovy® is used properly and responsibly for the treatment of obesity in consultation with a licensed healthcare professional.
At Novo Nordisk, patient safety is paramount. We want to reinforce that Wegovy® is the only semaglutide-containing Novo Nordisk medication approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adults with obesity or overweight with weight-related medical problems. This prescription-only medicine is available in a disposable single-use pen and should be prescribed in direct consultation with, and under the supervision of, a licensed healthcare professional. We support these medicines being prescribed to patients who meet the FDA-approved criteria and promote our medicines for those appropriate patients. Our other semaglutide-based products, Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg and RYBELSUS® (semaglutide) tablets 7 mg or 14 mg, which are indicated for adults with type 2 diabetes, have unique safety and efficacy profiles and are not FDA-approved for chronic weight management. Please see important product information, including the Prescribing Information for our semaglutide products at semaglutide.com.
Wegovy® is a prescription medication for people living with obesity, a serious and chronic disease. It has undergone a clinically rigorous FDA regulatory approval process. Novo Nordisk is the only manufacturer of the FDA-approved Wegovy®. We cannot validate the safety or effectiveness of products claiming to contain semaglutide that are not one of our own branded products. Click here to read more about our commitment to the responsible use of our medicines containing semaglutide, including our actions to address this important issue.
While we have already helped hundreds of thousands of people living with obesity, we recognize that many more people are counting on us. The demand for Wegovy® reinforces the unmet need and has strengthened our promise to not only develop innovative medicines but to partner, raise awareness, and advocate to change how obesity is understood, diagnosed, and treated.
If you are interested in Wegovy®, please discuss with your healthcare provider (HCP) if it might be right for you.
To see if Wegovy® is covered by your insurance, visit Wegovy.com or contact your insurance provider.
We’ve included some frequently asked questions below and are here to help if you need additional support at 1-833-4-WEGOVY (1-833-493-4689) from 9 AM to 6 PM Eastern Time Monday through Friday – and select option 0 for more support and at Wegovy.com.
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine that may help adults and children aged ≥12 years with obesity (BMI ≥30 for adults, BMI ≥ 95th percentile for age and sex for children), or some adults with excess weight (BMI ≥27) (overweight) who also have weight-related medical problems to help them lose weight and keep it off. Wegovy® should be used with a reduced calorie meal plan and increased physical activity